Alvotech Publishes 2025 Annual Report
Rhea-AI Summary
Alvotech (NASDAQ: ALVO) published its 2025 Annual Report on March 30, 2026. The report is available in the company's investor relations website and is attached to the announcement in PDF and iXBRL formats. Contact details for media and investors are provided for further inquiries.
Positive
- None.
Negative
- None.
Market Reality Check
Peers on Argus
ALVO gained 5.79% while key peers showed mixed, mostly modest moves (e.g., SUPN -1.06%, BHC -0.59%, ANIP +1.11%), pointing to stock-specific strength rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 18 | Earnings results | Positive | -5.8% | Strong Q4 and FY 2025 revenue and EBITDA with reaffirmed 2026 guidance. |
| Mar 04 | Earnings date set | Neutral | +2.4% | Announcement of date and time for Q4 and FY 2025 earnings release. |
| Feb 26 | Insider share transfer | Neutral | -4.1% | Intra‑group transfer of 2,701,617 shares within Aztiq-related entities. |
| Feb 11 | Share issuance | Negative | -6.7% | Capital increase via 12,500,000 new shares to subsidiary for obligations. |
| Feb 05 | Clinical data | Positive | -2.0% | Pivotal PK study for AVT80 met all primary endpoints vs Entyvio. |
Positive fundamental or clinical updates have often coincided with negative price reactions, while dilutive actions aligned with declines.
Over the last few months, Alvotech reported strong FY 2025 results with revenues of $593M and adjusted EBITDA of $137M, yet the stock fell 5.79% after that release. Earlier, a positive pivotal PK study for AVT80 versus Entyvio preceded a 1.96% drop. Share capital increases and internal share transfers were met with declines or muted reactions. Against this backdrop, the 2025 Annual Report publication follows a period where fundamentally positive news has not consistently translated into supportive price action.
Market Pulse Summary
This announcement flags the availability of Alvotech’s 2025 Annual Report, directing investors to detailed financials, risk factors and strategy. It follows FY 2025 revenue of $593M and adjusted EBITDA of $137M, plus recent clinical and regulatory milestones. With the stock trading near its $3.03 52-week low and below the $6.63 200-day MA, readers may focus on revenue guidance, pipeline execution, capital structure, and any disclosures around prior share transactions and leadership transition.
Key Terms
ixbrl technical
AI-generated analysis. Not financial advice.
REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has published its Annual Report for 2025. The report is available in the investor relations section of Alvotech’s website at: https://investors.alvotech.com/financials and is attached to this announcement in PDF and iXBRL formats.
For further information, contact:
Media
Benedikt Stefansson
Sarah MacLeod
alvotech.media@alvotech.com
Investors
Dr. Balaji V Prasad (US)
Patrik Ling (SE)
Benedikt Stefansson (IS)
alvotech.ir@alvotech.com
About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in biosimilars by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram and YouTube.
Attachments
FAQ
Where can investors download Alvotech's 2025 Annual Report (ALVO)?
What file formats are provided for Alvotech's 2025 Annual Report (ALVO)?
Who should media contact about Alvotech's 2025 Annual Report (ALVO)?
Who are the investor contacts for Alvotech regarding the 2025 Annual Report (ALVO)?
When was Alvotech's 2025 Annual Report published and which ticker does it concern (ALVO)?
